Glaxo Zantac 75 Divestiture To W-L Required By FTC
This article was originally published in The Tan Sheet
Executive Summary
Glaxo Wellcome has agreed to sell trademark rights and other controls over the marketing of OTC Zantac 75 to Warner-Lambert Consumer Group in order to complete its merger with SmithKline Beecham in accordance with a proposed consent order issued by the Federal Trade Commission Dec. 18.
You may also be interested in...
Pfizer Looks To Give J&J/Merck Heartburn With Zantac 150 Switch
Pfizer Consumer Healthcare's Rx-to-OTC switch of Zantac 150 appears to be a belated attempt to counter Johnson & Johnson/Merck's approval of Maximum Strength Pepcid AC last year
Pfizer Looks To Give J&J/Merck Heartburn With Zantac 150 Switch
Pfizer Consumer Healthcare's Rx-to-OTC switch of Zantac 150 appears to be a belated attempt to counter Johnson & Johnson/Merck's approval of Maximum Strength Pepcid AC last year
Pfizer Looks To Give J&J/Merck Heartburn With Zantac 150 Switch
Pfizer Consumer Healthcare's Rx-to-OTC switch of Zantac 150 appears to be a belated attempt to counter Johnson & Johnson/Merck's approval of Maximum Strength Pepcid AC last year